Kura Oncology, Inc.
Kura Oncology, Inc.（KURA）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · KURA · 截至 2026年6月9日
活动摘要
买入笔数
3
P-Purchase only
卖出笔数
33
近12个月
买卖比
0.09
Buy/Sell (by trades)
整体情绪
Kura Oncology, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
KURA 季度内部人买卖趋势
KURA 内幕交易卖出 · KURA 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · KURA CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
KURA 高管卖出股份 · KURA 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 21, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 10,000 | $110K | Form 4 |
| May 19, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 339 | $3K | Form 4 |
| May 19, 2026 | FORD KATHLEEN COO | Sale | 2,257 | $20K | Form 4 |
| May 18, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale | 2,256 | $21K | Form 4 |
| Mar 23, 2026 | WILSON TROY EDWARD President and CEO · Director | Option | 6,103 | $38K | Form 4 |
| Mar 18, 2026 | Malley Thomas Director | Option | 10,000 | $31K | Form 4 |
| Jan 27, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 4,842 | $41K | Form 4 |
| Jan 27, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 1,572 | $13K | Form 4 |
| Jan 27, 2026 | FORD KATHLEEN COO | Sale | 1,813 | $15K | Form 4 |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 3,655 | $31K | Form 4 |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 2,233 | $19K | Form 4 |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 951 | $8K | Form 4 |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 1,341 | $11K | Form 4 |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 2,226 | $19K | Form 4 |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 1,114 | $9K | Form 4 |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 695 | $6K | Form 4 |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 2,226 | $19K | Form 4 |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 881 | $7K | Form 4 |
| Jan 27, 2026 | Burrows Francis Chief Scientific Officer | Sale | 1,311 | $11K | Form 4 |
| Jan 27, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale | 4,096 | $35K | Form 4 |
| Jan 27, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale | 2,335 | $20K | Form 4 |
| Jan 27, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale | 4,777 | $40K | Form 4 |
| Jan 2, 2026 | Leoni Mollie Chief Medical Officer | Award | 50,000 | — | Form 4 |
| Jan 2, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Award | 21,250 | — | Form 4 |
| Jan 2, 2026 | FORD KATHLEEN COO | Award | 50,000 | — | Form 4 |
WILSON TROY EDWARD
President and CEO · Director
日期
Mar 23
股数
6,103
均价
$6.15
总金额
$38K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 KURA 内幕交易
KURA 内幕交易
Kura Oncology, Inc.（KURA）内幕交易数据来源于公司内部人（包括DOYLE THOMAS JAMES (SVP, Finance & Accounting), Powl Brian T. (Chief Commercial Officer), Bair Teresa Brophy (Chief Legal Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。KURA内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Kura Oncology, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
KURA 内幕交易 · 5个问题Kura Oncology, Inc.（KURA）的内部人包括高管和董事，如DOYLE THOMAS JAMES (SVP, Finance & Accounting), Powl Brian T. (Chief Commercial Officer), Bair Teresa Brophy (Chief Legal Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026